DHR Danaher Corporation
A quality consumables franchise in recovery, but the price already assumes peak-like margins return quickly.
The story
Danaher is a razor/razorblade life-sciences tools franchise: bioprocessing consumables (Cytiva, Pall), diagnostics (Beckman, Cepheid, Radiometer) and recurring reagents, held together by the Danaher Business System. The post-COVID destocking slump has ended. TTM revenue is up about 4% to 25.6B and the GAAP operating margin has recovered from 18.3% to 20.2%. It is now a mature compounder in early cyclical recovery, not a growth story, and the acquisition-heavy balance sheet keeps reported returns on capital low.
The recovery is now visible in both revenue and margin, so I nudged year-1 growth up to 6.5% and the target margin to 29%. That margin is near the pre-COVID-normal level after amortization, not the 2021 peak. Sales-to-capital moves from 1.0 to 1.2 (+20%) because organic growth is capital-light: capex of 1.13B is well below D&A of 2.63B. The 0.36 reported figure is inflated by goodwill and should not drive incremental reinvestment. My value still sits well below the price, which tells me the market is pricing a faster, fuller margin snap-back than I can justify at a 5% risk-free rate.
Value drivers
| Revenue growth (Y1) | 6.5% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 29.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.20 |
| Beta | 0.95 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.9% |
| Terminal WACC | 9.1% |
Valuation bridge
| PV of explicit FCFF | 40.88B |
| PV of terminal value | 49.42B |
| Equity value | 74.07B |
| ÷ shares → per share | $105.29 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 27.27B | 6.5% | 22.0% | 5.10B | 1.39B | 3.71B | 3.41B |
| 2 | 28.95B | 6.2% | 23.7% | 5.84B | 1.40B | 4.44B | 3.74B |
| 3 | 30.64B | 5.8% | 25.5% | 6.64B | 1.41B | 5.23B | 4.05B |
| 4 | 32.33B | 5.5% | 27.2% | 7.49B | 1.40B | 6.09B | 4.32B |
| 5 | 34.00B | 5.2% | 29.0% | 8.39B | 1.39B | 6.99B | 4.56B |
| 6 | 35.64B | 4.8% | 29.0% | 8.79B | 1.37B | 7.42B | 4.44B |
| 7 | 37.25B | 4.5% | 29.0% | 9.19B | 1.34B | 7.85B | 4.31B |
| 8 | 38.80B | 4.2% | 29.0% | 9.57B | 1.29B | 8.28B | 4.17B |
| 9 | 40.29B | 3.8% | 29.0% | 9.94B | 1.24B | 8.70B | 4.02B |
| 10 | 41.70B | 3.5% | 29.0% | 10.28B | 1.17B | 9.11B | 3.87B |
Key risks
- Bioprocessing recovery stalls as biotech funding and China demand stay weak
- Margin recovery capped by acquisition amortization, pricing pressure and diagnostics normalization
- Large, expensive M&A that further dilutes return on capital
Catalysts
- Sustained bioprocessing order growth and a return to high-single-digit core growth
- Operating margin re-expanding toward the mid-to-high 20s on volume leverage